Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 7;33:2058738419841482. doi: 10.1177/2058738419841482

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 6. — Expression of (a) p-GSK3β and (b) p-mTOR in the hippocampus of APP/PS1 transgenic mice was determined by western blotting. Control: C57BL/6J mice; APP: APP/PS1 mice; APP + D: donepezil; APP + Gs: GAPT small dose; APP + Gm: GAPT middle dose; APP + Gh: GAPT high dose. **P < 0.01 versus control group, △P < 0.05 versus model group, △△P < 0.01 versus model group; ANOVA. Compared with the model group, the expression of p-GSK3β in the donepezil group, GAPT high- and small-dose groups were increased (P < 0.05), while the expression of p-GSK3β in the GAPT middle-dose group was significantly increased (P < 0.01). The expression of p-mTOR in the donepezil group was decreased (P < 0.05), while the expression of p-mTOR in the GAPT high- and middle-dose groups was significantly decreased (P < 0.01).